Stryker entered into an agreement to distribute AlloSource biologic products in the U.S. for use in sports medicine procedures.
We expect that Stryker will continue to launch products and collaborate in the arthroscopy/soft tissue and orthobiologics spaces to boost its sports medicine portfolio. Leadership has noted that, while sports medicine is a small portion of the company’s revenue, it’s “growing very fast.” Stryker’s 2015, 2016 and 1Q17 revenue for arthroscopy/soft tissue and orthobiolgics can be found here.
Stryker entered into an agreement to distribute AlloSource biologic products in the U.S. for use in sports medicine procedures.
We expect that Stryker will continue to launch products and collaborate in the arthroscopy/soft tissue and orthobiologics spaces to boost its sports medicine portfolio. Leadership has noted that, while sports...
Stryker entered into an agreement to distribute AlloSource biologic products in the U.S. for use in sports medicine procedures.
We expect that Stryker will continue to launch products and collaborate in the arthroscopy/soft tissue and orthobiologics spaces to boost its sports medicine portfolio. Leadership has noted that, while sports medicine is a small portion of the company’s revenue, it’s “growing very fast.” Stryker’s 2015, 2016 and 1Q17 revenue for arthroscopy/soft tissue and orthobiolgics can be found here.
Copy to clipboard 
